The implications of measuring lipoprotein(a) in clinical practice
DOI:
https://doi.org/10.21542/gcsp.2024.40Abstract
Lipoprotein(a) (Lp(a)) is a well-recognized causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis. There are ongoing challenges with screening and management in primary and secondary prevention; however, future recommendations for clinical practice await the outcomes of clinical trials that are in progress.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Mahmoud Barbir, Alison Pottle, Stefan R. Bornstein
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open access article distributed under the terms of the Creative Commons Attribution license CC BY 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.